Recently approved for use in Europe and UK, the test is currently going through United States FDA approval and the airline is the first in the world to trial the new technology. Subject an evaluation, the airline hopes to be able to offer the test technology on applicable routes where tests have to meet the stated specificity and sensitivity standards.
The test is a non-invasive saliva ultra-rapid digital antigen test that delivers 98 percent sensitivity and 100 percent specificity in symptomatic and asymptomatic individuals with SARS-CoV-2. Users simply take a sample of their saliva into a disposable sensor unit, shake and insert it into a re-usable digital reader which is connected to a blue-tooth enabled device like a smartphone, and then wait for the results that appear through a mobile app.
Sean Doyle, Chief Executive, British Airways said in a statement that as the airline starts to see the opening up of travel, it will remain committed to exploring easy and affordable testing solutions to help customers travel again, whether it is for business, to reunite with family and friends or take a much-needed break abroad. He shared that the new ultra-rapid test is a game changer so authorities are delighted to work with the team at Canary to begin initial trials with flight and cabin crew, before exploring what role it could play as a customer testing option.
Tags: British Airways, Covid-19
